FDA Still Casts Shadow On CBD Win

Jan 14, 2019

With CBD making strides in the recent signing of the farm bill, the FDA still cast a shadow on said win with a statement warning CBD entrepreneurs. "Selling unapproved products with unsubstantiated therapeutic claims is not only a violation of the law, but also can put patients at risk, as these products have not been proven to be safe or effective." The FDA Commissioner Scott Gottlieb wrote the statement just days after the ‘new’ farm bill was signed by President Trump. 

But what does this mean for CBD oil? The FDA has sent warning letters to some companies making health claims for CBD. Why? Because the legal status of CBD is still murky. While the FDA has promised to help make legal pathways in the moving forward of CBD oil, they also want you to know that the law states you cannot advertise that products treat disease. Some of these claims have even been seen as social media violations which lead to the shutdown of several CBD oil social media pages. 

In June we saw the appearance of the FDA-approved drug for the treatment of seizures, Epidiolex, which contains cannabis-derived CBD. Manufactured by GW Pharmaceuticals the syrup became the first prescription drug derived from the cannabis plant. So while the FDA is still casting a shadow for CBD oil tinctures, gummies, lotions, food, and drinks - there are strides being made. 

The FDA statement also said, “three ingredients derived from hemp: hulled hemp seeds, hemp seed protein and hemp seed oil -- are safe as foods and won't require additional approvals, as long as marketers do not make claims that they treat disease.” For now, CBD is still on the fence of what’s legal and what’s not, and will likely remain that way for many months to come.